FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 228 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,761 | -69.6% | 537 | -31.9% | 0.00% | -100.0% |
| Q1 2024 | $5,791 | +238.9% | 789 | +72.6% | 0.00% | – |
| Q4 2023 | $1,709 | -78.7% | 457 | -67.5% | 0.00% | -100.0% |
| Q1 2023 | $8,020 | +143.8% | 1,407 | +331.6% | 0.00% | – |
| Q4 2022 | $3,289 | -34.2% | 326 | +57.5% | 0.00% | -100.0% |
| Q3 2022 | $5,000 | -16.7% | 207 | -11.9% | 0.00% | 0.0% |
| Q2 2022 | $6,000 | -14.3% | 235 | +23.7% | 0.00% | 0.0% |
| Q1 2022 | $7,000 | -78.8% | 190 | -65.8% | 0.00% | -80.0% |
| Q4 2021 | $33,000 | +1550.0% | 556 | +1444.4% | 0.01% | +400.0% |
| Q3 2021 | $2,000 | -33.3% | 36 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $3,000 | -50.0% | 36 | -47.8% | 0.00% | 0.0% |
| Q1 2021 | $6,000 | +100.0% | 69 | +91.7% | 0.00% | 0.0% |
| Q4 2020 | $3,000 | – | 36 | +200.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 12 | -97.7% | 0.00% | -100.0% |
| Q2 2020 | $18,000 | +1700.0% | 512 | +1090.7% | 0.01% | – |
| Q1 2020 | $1,000 | -97.4% | 43 | -97.8% | 0.00% | -100.0% |
| Q4 2019 | $39,000 | – | 2,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |